Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (2020 - 2025)

Ovid Therapeutics' Shares Outstanding history spans 6 years, with the latest figure at $130.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 83.33% year-over-year to $130.2 million; the TTM value through Dec 2025 reached $130.2 million, up 83.33%, while the annual FY2025 figure was $130.2 million, 83.33% up from the prior year.
  • Shares Outstanding reached $130.2 million in Q4 2025 per OVID's latest filing, up from $71.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $130.2 million in Q4 2025 to a low of $1250.0 in Q3 2021.
  • Average Shares Outstanding over 5 years is $63.2 million, with a median of $70.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: tumbled 100.0% in 2021, then skyrocketed 5633451.04% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $7.3 million in 2021, then skyrocketed by 865.3% to $70.5 million in 2022, then increased by 0.32% to $70.7 million in 2023, then increased by 0.45% to $71.0 million in 2024, then skyrocketed by 83.33% to $130.2 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Shares Outstanding are $130.2 million (Q4 2025), $71.2 million (Q3 2025), and $71.1 million (Q2 2025).